New combo aims to free ITP patients from lifelong medication
NCT ID NCT07278908
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding all-trans retinoic acid (ATRA) to the drug avatrombopag can help adults with immune thrombocytopenia (ITP) maintain normal platelet levels without needing ongoing treatment. About 248 participants who have not responded well to first-line therapy or have relapsed will be randomly assigned to receive either avatrombopag alone or avatrombopag plus ATRA for up to 24 weeks, followed by a tapering period. The main goal is to see how many people can stop all treatment and still have safe platelet counts at one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avatrombopag and all-trans retinoic acid
What this could lead to
If it works, this combination could help more people with ITP stop taking medication for a longer time, reducing the need for ongoing treatment.
What could go wrong
This is an early-to-mid stage trial with only 248 people, so results may not apply to everyone. The combination may cause side effects like headache, nausea, or liver issues, and it's not yet proven to be better than avatrombopag alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.